Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03166631
Recruitment Status : Completed
First Posted : May 25, 2017
Last Update Posted : March 3, 2021
Sponsor:
Information provided by (Responsible Party):
Boehringer Ingelheim

Tracking Information
First Submitted Date  ICMJE May 23, 2017
First Posted Date  ICMJE May 25, 2017
Last Update Posted Date March 3, 2021
Actual Study Start Date  ICMJE September 8, 2017
Actual Primary Completion Date September 15, 2020   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: August 1, 2017)
  • Part A - Maximum tolerated dose of BI 891065 [ Time Frame: 9 months ]
  • Part A - number of patients with Dose-limiting toxicities (DLTs) during the first treatment cycle. [ Time Frame: 3 weeks ]
  • Part B - Maximum tolerated dose of BI 891065 in combination with BI 754091 [ Time Frame: 9 months ]
  • Part B - number of patients with Dose-limiting toxicities (DLTs) during the first treatment cycle. [ Time Frame: 3 weeks ]
  • Part C - Objective response (OR) is defined as best overall response of Complete response (CR) or partial response (PR), where best overall response is determined according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 [ Time Frame: 18 weeks ]
Original Primary Outcome Measures  ICMJE
 (submitted: May 24, 2017)
  • Part A - Maximum tolerated dose of BI 891065 [ Time Frame: 9 months ]
  • Part A - number of patients with Dose-limiting toxicities (DLTs) during the first treatment cycle. [ Time Frame: 3 weeks ]
  • Part B - Maximum tolerated dose of BI 891065 in combination with BI 754091 [ Time Frame: 9 months ]
  • Part B - number of patients with Dose-limiting toxicities (DLTs) during the first treatment cycle. [ Time Frame: 3 weeks ]
  • Part C - Objective response (OR) is defined as best overall response of Complete response (CR) or partial response (PR), where best overall response is determined according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 [ Time Frame: 18 weeks ]
  • Part C-Objective response is defined as a best overall response of stringent complete response (sCR), CR, very good partial response (VGPR), or PR, where best overall response is determined according to International Myeloma Working Group (IMWG) criteria [ Time Frame: 18 weeks ]
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: August 1, 2017)
  • Part A - The number of patients with Dose-limiting toxicities (DLTs) observed during the entire treatment period. [ Time Frame: 12 months ]
  • Part A - Cmax(,ss) of BI 891065 in the first treatment cycle. [ Time Frame: 3 weeks ]
  • Part A - Objective response (OR) based on RECIST v1.1. [ Time Frame: 12 months ]
  • Part B - The number of patients with Dose-limiting toxicities (DLTs) observed during the entire treatment period. [ Time Frame: 12 months ]
  • Part B - Cmax(,ss) of BI 891065 [ Time Frame: 3 weeks ]
  • Part B - Objective response (OR) based on RECIST v1.1. [ Time Frame: 12 months ]
  • Part C - Duration of Objective response (OR) based on RECIST 1.1 (for the NSCLC cohort) [ Time Frame: 18 months ]
  • Part A - AUC0-tz of BI 891065 in the first treatment cycle. [ Time Frame: 3 weeks ]
  • Part A - AUC tau,ss of BI 891065 in the first treatment cycle. [ Time Frame: 3 weeks ]
  • Part B - AUC0-tz of BI 891065 [ Time Frame: 3 weeks ]
  • Part B - AUCtau,ss of BI 891065 [ Time Frame: 3 weeks ]
  • Part B - Cmax of BI 754091 in the first treatment cycle. [ Time Frame: 3 weeks ]
  • Part B - AUC0-tz of BI 754091 in the first treatment cycle. [ Time Frame: 3 weeks ]
Original Secondary Outcome Measures  ICMJE
 (submitted: May 24, 2017)
  • Part A - The number of patients with Dose-limiting toxicities (DLTs) observed during the entire treatment period. [ Time Frame: 12 months ]
  • Part A - Cmax(,ss) of BI 891065 in the first treatment cycle. [ Time Frame: 3 weeks ]
  • Part A - Objective response (OR) based on RECIST v1.1. [ Time Frame: 12 months ]
  • Part B - The number of patients with Dose-limiting toxicities (DLTs) observed during the entire treatment period. [ Time Frame: 12 months ]
  • Part B - Cmax(,ss) of BI 891065 [ Time Frame: 3 weeks ]
  • Part B - Objective response (OR) based on RECIST v1.1. [ Time Frame: 12 months ]
  • Part C - Duration of Objective response (OR) based on RECIST 1.1 (for the NSCLC cohort) or on IMWG criteria (for the MM cohort) [ Time Frame: 18 months ]
  • Part A - AUC0-tz of BI 891065 in the first treatment cycle. [ Time Frame: 3 weeks ]
  • Part A - AUC tau,ss of BI 891065 in the first treatment cycle. [ Time Frame: 3 weeks ]
  • Part B - AUC0-tz of BI 891065 [ Time Frame: 3 weeks ]
  • Part B - AUCtau,ss of BI 891065 [ Time Frame: 3 weeks ]
  • Part B - Cmax of BI 754091 in the first treatment cycle. [ Time Frame: 3 weeks ]
  • Part B - AUC0-tz of BI 754091 in the first treatment cycle. [ Time Frame: 3 weeks ]
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread
Official Title  ICMJE An Open-label Phase I Dose Finding Trial With BI 891065 Alone and in Combination With BI 754091 to Characterise Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy in Patients With Advanced and/or Metastatic Malignancies
Brief Summary

The main objective of the dose-escalation parts of the trial is to determine the maximum tolerated dose (MTD), based on the frequency of patients experiencing dose-limiting toxicities (DLTs), and/or the recommended dose for further development of BI 891065 monotherapy as well as of BI 891065 in combination with BI 754091, and to evaluate its safety and tolerability by monitoring the occurrence and severity of adverse events (AEs).

Secondary objectives are the determination of the pharmacokinetic (PK) profile of BI 891065 monotherapy as well as of BI 891065 in combination with BI 754091, and the preliminary assessment of anti-tumour activity.

Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Neoplasms
  • Neoplasm Metastasis
  • Carcinoma, Non-Small-Cell Lung
Intervention  ICMJE
  • Drug: BI 891065
    Part A, B & C
  • Drug: BI 754091
    Part B & C
Study Arms  ICMJE
  • Experimental: Part A
    BI 891065 alone (Solid Tumours)
    Intervention: Drug: BI 891065
  • Experimental: Part B
    BI 891065 in combination with BI 754091 (Solid Tumours)
    Interventions:
    • Drug: BI 891065
    • Drug: BI 754091
  • Experimental: Part C
    BI 891065 in combination with BI 754091 (Non Small Cell Lung Cancer)
    Interventions:
    • Drug: BI 891065
    • Drug: BI 754091
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: October 21, 2020)
62
Original Estimated Enrollment  ICMJE
 (submitted: May 24, 2017)
113
Actual Study Completion Date  ICMJE October 28, 2020
Actual Primary Completion Date September 15, 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion criteria:

  • Provision of signed and dated, written ICF in accordance with ICH-GCP and local legislation prior to any trial-specific procedures, sampling, or analyses
  • Patients ≥18 years-of-age at the time of signature of the ICF
  • Male or female patients. Women of childbearing potential (WOCBP) and men able to father a child must be ready and able to use highly effective methods of birth control (that result in a low failure rate of less than 1% per year when used consistently and correctly)during trial participation and for at least 6 months after the last administration of trial medication. A list of contraception methods meeting these criteria is provided in the patient information.
  • Eastern Cooperative Oncology Group (ECOG) score: 0 or 1
  • Life expectancy of at least 12 weeks after the start of the treatment according to the Investigator's judgement
  • For Parts A and B: Patients with a confirmed diagnosis of advanced, unresectable and/or metastatic solid tumours, who have failed standard treatment, or for whom no therapy of proven efficacy exists, or who are not amenable to standard therapies. Measurable lesions according to RECIST Version 1.1 must be present. Eligibility is limited to the following tumour subtypes in Part B: bladder, colon, breast, Non-small cell lung cancer (NSCLC), ovarian, pancreatic, renal, esophagogastric, sarcoma, prostate, and melanoma.
  • For Parts B and C: Patients must have measurable disease per RECIST v1.1, must have at least 1 tumour lesion amenable to biopsy, and must be willing to undergo a biopsy prior to first treatment and another biopsy while on therapy unless clinically contraindicated.
  • For Part C: Patients with metastatic NSCLC who developed disease progression (per RECIST v1.1) after the first scan (where SD, PR, or CR was demonstrated at the first scan), and require new anti-cancer therapy after first line treatment with an anti PD-1/anti PD-L1 mAb (given either as single agent therapy or in combination with a platinum-based chemotherapy regimen).

Exclusion criteria:

  • Major surgery (major according to the Investigator's and/or Medical Monitor's assessment) performed within 12 weeks prior to randomization or planned within 12 months after screening (e.g., hip replacement)
  • Presence of other active invasive cancers other than the one treated in this trial within 5 years prior to screening, except appropriately treated basal cell carcinoma of the skin, or in situ carcinoma of uterine cervix, or other local tumours considered cured by local treatment
  • Patients who must or wish to continue the intake of restricted medications or any drug considered likely to interfere with the safe conduct of the trial
  • Previous administration of BI 891065 or BI 754091
  • Currently enrolled in another investigational device or drug trial, or less than 30 days since ending another investigational device or drug trial(s), or receiving other investigational treatments.
  • Patients who have been treated with any other anticancer drug within 4 weeks or within 5 half-life periods (whichever come earlier) prior to first administration of BI 891065. At least 7 days must have elapsed between the last dose of such agent and the first dose of study drug.
  • Persistent toxicity from previous treatments that has not resolved to ≤ Grade 1 (except for alopecia and Grade 2 neuropathy due to prior platinum-based therapy)
  • Active, known or suspected autoimmune disease except vitiligo or resolved asthma/atopy
  • Interstitial lung disease
  • Any of the following cardiac criteria:

    • Mean resting corrected QT interval (QTcF) >470 msec
    • Any clinically important abnormalities (as assessed by the investigator) in rhythm, conduction, or morphology of resting ECGs, e.g., complete left bundle branch block, third degree heart block
    • Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalaemia, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years-of-age, or any concomitant medication with known or possible risk of QT interval prolongation
    • Patients with an ejection fraction (EF) <55% or the lower limit of normal of the institutional standard will be excluded. Only in cases where the Investigator (or the treating physician or both) suspects cardiac disease with negative effect on the EF, will the EF be measured during screening using an appropriate method according to local standards to confirm eligibility (e.g., echocardiogram [ECHO], multi-gated acquisition scan [MUGA]). A historic measurement of EF no older than 6 months prior to first administration of study drug can be accepted provided that there is clinical evidence that the EF value has not worsened since this measurement in the opinion of the Investigator or of the treating physician or both.
  • Out of range laboratory values are defined as:

    • Alanine transaminase (ALT) and aspartate amino transferase (AST) >3 times the ULN if no demonstrable liver metastases or >5 times ULN in the presence of liver metastases
    • Total bilirubin >1.5 times ULN, except for patients with Gilbert's syndrome who are excluded if total bilirubin >3.0 times ULN or direct bilirubin >1.5 times ULN
  • Human immunodeficiency virus (HIV) infection, acute or chronic viral hepatitis
  • Known hypersensitivity to the trial drugs or their excipients
  • Serious concomitant disease or medical condition affecting compliance with trial requirements or which are considered relevant for the evaluation of the efficacy or safety of the trial drug, such as cardiac, neurologic, psychiatric, infectious disease or active ulcers (gastro-intestinal tract, skin) or laboratory abnormality that may increase the risk associated with trial participation or trial drug administration, and in the judgment of the Investigator and/or Medical Monitor would make the patient inappropriate for entry into the trial.
  • Chronic alcohol or drug abuse or any condition that, in the Investigator's and/or Medical Monitor's opinion, makes them an unreliable trial patient or unlikely to complete the trial
  • Women who are pregnant, nursing, or who plan to become pregnant while in the trial and for at least 6 months after the last administration of trial medication.
  • Men who plan to father a child while in the trial and for at least 6 months after the last administration of trial medication.
  • Known presence of symptomatic central nervous system (CNS) metastases, unless asymptomatic and off corticosteroids and/or anti-convulsant therapy for at least 2 weeks prior start of treatment. Patients with asymptomatic CNS metastases may be enrolled following a 2-week washout period.
  • Patients receiving systemic treatment with any immunosuppressive medication within 1 week prior treatment start (steroids of max. 10 mg prednisolone equivalent per day are allowed, topical and inhaled steroids are not considered as immunosuppressive).
  • For Parts A and B: Patients with known epidermal growth factor receptor (EGFR), known anaplastic lymphoma kinase (ALK), or known ROS Proto-Oncogene 1 (ROS1) genomic tumour aberrations, unless disease has progressed following available EGFR or ALK targeted therapy (including osimertinib for EGFR T790M-mutated NSCLC)
  • Out of range lab values as defined:

    • Absolute neutrophil count (ANC) <1.5 x 109/L (<1500/mm3)
    • Platelet (PLT) count <100 x 109/L
  • Haemoglobin <90 g/L (<9 g/dL)

    -- Creatinine >1.5 times ULN (patients may enter if creatinine is >1.5 x ULN and estimated glomerular filtration rate (eGFR) >30 mL/min/1.73 m2) (Chronic Kidney Disease Epidemiology [CKD-EPI] Collaboration equation); confirmation of eGRF is only required when creatinine is >1.5 X ULN.

  • For Part C: Patients with EGFR, ALK, or (if known) ROS1 genomic tumor aberrations
  • For Part C: Patients with any CTLA-4 therapy
  • For Part C: One or more lines of anti-cancer therapy between previous anti-PD-1/anti-PDL1 mAb therapy and study entry.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03166631
Other Study ID Numbers  ICMJE 1379-0001
2017-000465-74 ( EudraCT Number )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Boehringer Ingelheim
Study Sponsor  ICMJE Boehringer Ingelheim
Collaborators  ICMJE Not Provided
Investigators  ICMJE Not Provided
PRS Account Boehringer Ingelheim
Verification Date March 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP